1.85

3.93% 0.07

After Hours: 1.89 0.04 +2.16%

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $1.85, with a volume of 504.27K. It is up +3.93% in the last 24 hours and down -3.65% over the past month. Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Previous Close:

$1.78

Open:

$1.8

24h Volume:

504.27K

Relative Volume:

0.71

Market Cap:

$64.55M

Revenue:

$832.00K

Net Income/Loss:

$-135.12M

P/E Ratio:

-0.3038

EPS:

-6.09

Net Cash Flow:

$-124.69M

1W Performance:

+5.11%

1M Performance:

-3.65%

6M Performance:

-67.54%

1Y Performance:

-81.54%

1-Day Range:

$1.78

$1.86

1-Week Range:

$1.675

$1.9192

52-Week Range:

$1.42

$13.44

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (665)

Phone

(858) 410-3134

Address

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Employee

134

Twitter

@inoviopharma

Next Earnings Date

2024-11-07

Latest SEC Filings

INO's Discussions on Twitter

Compare INO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO Inovio Pharmaceuticals Inc	1.85	64.55M	832.00K	-135.12M	-124.69M	-6.09
VRTX Vertex Pharmaceuticals Inc	490.47	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	585.49	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.87	36.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.75	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.77	25.74B	3.81B	-644.79M	-669.77M	-6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-14-24	Initiated	Stephens	Overweight
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

05:25 AM

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

05:25 AM

Apr 21, 2025

Bet on These 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance

Apr 21, 2025

Apr 17, 2025

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN

Apr 17, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 16, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Apr 16, 2025

Apr 11, 2025

Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch

Apr 11, 2025

INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN

Apr 11, 2025

INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo

Apr 11, 2025

Apr 10, 2025

Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal

Apr 09, 2025

INOVIO's Breakthrough: 72% Success in HPV TreatmentMultiple Conference Spotlights - Stock Titan

Apr 09, 2025

Apr 08, 2025

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 08, 2025

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 04, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 04, 2025

Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire

Apr 04, 2025

Apr 02, 2025

HPV Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR | - openPR.com

Apr 02, 2025

Apr 01, 2025

Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Sector Update: Health Care - MarketScreener

Mar 31, 2025

Mar 28, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 28, 2025

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 25, 2025

Lassa Fever Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Inovio Pharma - Barchart.com

Mar 25, 2025

Mar 22, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 21, 2025

INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes - MSN

Mar 21, 2025

Mar 20, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 20, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead By Investing.com - Investing.com South Africa

Mar 20, 2025

DNA Vaccines Market and Their Impact on Global Health: Trends & - openPR.com

Mar 20, 2025

Mar 19, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead - Investing.com

Mar 19, 2025

Inovio taking on Covid-19 again, almost 3 years after abandoning vaccine effort - Philadelphia Business Journal

Mar 19, 2025

Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues - MSN

Mar 19, 2025

RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk - Marketscreener.com

Mar 19, 2025